mouse anti human cd56 monoclonal  (OriGene)

Journal: eLife

Article Title: JAK inhibition decreases the autoimmune burden in Down syndrome

doi: 10.7554/eLife.99323

Figure Lengend Snippet:

Article Snippet: Antibody , Mouse monoclonal anti-human CD56 (clone N901) , Fluidigm , Cat # 3176009B; RRID: AB_2811096 , Lot 3171701, 1:50.

Techniques: Isolation, Biomarker Assay, Staining, Antibody Labeling, Software, Sequencing

Journal: Experimental and Therapeutic Medicine

Article Title: Overexpression of ELF1 combined with MMP9 is associated with prognosis and tumor microenvironment in gastric cancer

doi: 10.3892/etm.2024.12730

Figure Lengend Snippet: Association between ELF1 expression by tissue microarray-immunohistochemistry and that of different immune cell markers in GC.

Article Snippet: Subsequently, mouse antihuman ELF1 polyclonal antibody (dilution 1:400; cat. no. 22565-1-AP; ProteinTech Group, Inc.), MMP9 polyclonal antibody (dilution 1:300; cat. no. 10375-2-AP; ProteinTech Group, Inc.), mouse anti-human CD19 monoclonal (ready to use; cat. no. ZM-0038; ZSGB-BIO; OriGene Technologies, Inc.), mouse anti-human CD3 monoclonal (ready to use; cat. no. ZM-0417; ZSGB-BIO; OriGene Technologies, Inc.), mouse antihuman CD4 monoclonal (ready to use; cat. no. ZM-0418; ZSGB-BIO; OriGene Technologies, Inc.), rabbit anti-human CD8 monoclonal (ready to use; cat. no. ZM-0508 ZSGB-BIO; OriGene Technologies, Inc.) and mouse anti-human CD56 monoclonal (ready to use; cat. no. ZM-0057; ZSGB-BIO; OriGene Technologies, Inc.) were used for staining overnight at 4˚C.

Techniques: Expressing, Microarray, Significance Assay

Journal: Experimental and Therapeutic Medicine

Article Title: Overexpression of ELF1 combined with MMP9 is associated with prognosis and tumor microenvironment in gastric cancer

doi: 10.3892/etm.2024.12730

Figure Lengend Snippet: Association of ELF1 with CD19, CD3, CD4, CD8 and CD56 detected through immunohistochemical analysis. Magnification, x100; Scale bars, 250 µm). The red arrow indicates area of high protein expression, whilst the green arrow indicates areas of low protein expression. Upper, GC with ELF1 (+); lower, GC with ELF1 (-). ELF1, E74-like Factor 1.

Article Snippet: Subsequently, mouse antihuman ELF1 polyclonal antibody (dilution 1:400; cat. no. 22565-1-AP; ProteinTech Group, Inc.), MMP9 polyclonal antibody (dilution 1:300; cat. no. 10375-2-AP; ProteinTech Group, Inc.), mouse anti-human CD19 monoclonal (ready to use; cat. no. ZM-0038; ZSGB-BIO; OriGene Technologies, Inc.), mouse anti-human CD3 monoclonal (ready to use; cat. no. ZM-0417; ZSGB-BIO; OriGene Technologies, Inc.), mouse antihuman CD4 monoclonal (ready to use; cat. no. ZM-0418; ZSGB-BIO; OriGene Technologies, Inc.), rabbit anti-human CD8 monoclonal (ready to use; cat. no. ZM-0508 ZSGB-BIO; OriGene Technologies, Inc.) and mouse anti-human CD56 monoclonal (ready to use; cat. no. ZM-0057; ZSGB-BIO; OriGene Technologies, Inc.) were used for staining overnight at 4˚C.

Techniques: Immunohistochemical staining, Expressing

Journal: Neoplasia (New York, N.Y.)

Article Title: Construction of self-driving anti-αFR CAR-engineered NK cells based on IFN-γ and TNF-α synergistically induced high expression of CXCL10

doi: 10.1016/j.neo.2024.101065

Figure Lengend Snippet: In vivo antitumor activity and chemotaxis of NK-92-αFR-CAR-CXCR3A cells. (A), (E) Schematic representation of the construction of different mouse xenograft models of ovarian cancer and the corresponding treatment protocols. s.c. represents subcutaneous injection, i.v. represents intravenous injection, i.p. represents intraperitoneal injection. (B) Subcutaneous tumor tissues were isolated for photographing at the endpoint of the animal study. (C) Subcutaneous tumor volumes of each group were estimated every two days to monitor ovarian cancer development. (D) Chemotactic migration of NK-92 cells into subcutaneous tumor tissues were detected using immunohistochemistry. On the top was a representative immunohistochemistry picture of each group. Scale bars: 100 µm. On the bottom was quantification summary of CD56 positive stained cells per field view in each group. Five randomly selected fields of view were quantified for each group. (F) Intraperitoneal tumor development was determined by in vivo bioluminescence imaging at day 0 and day 14. (G) Statistical analysis of bioluminescence signal intensity in each group shown in (F). (H) Kaplan-Meier survival curves of intraperitoneal tumor-bearing mice treated with PBS, NK-92-EV cells, NK-92-αFR-CAR cells, or NK-92-αFR-CAR-CXCR3A cells. The data in (C), (D), and (G) are expressed as the means ± SEM of five mice for all groups. Statistical analysis shows the comparison between the labeled groups. * represents significant difference, * P < 0.05; ** P < 0.01; ns, P ≥ 0.05.

Article Snippet: The sections were blocked with 10 % goat serum (Beyotime) at 37 °C for 30 min and incubated with mouse anti-human NCAM1 (CD56) mAb (Cell Signaling Technology) at 4 °C overnight.

Techniques: In Vivo, Activity Assay, Chemotaxis Assay, Injection, Isolation, Migration, Immunohistochemistry, Staining, Imaging, Comparison, Labeling

Journal: Veterinární Medicína

Article Title: An unusual finding of schwannoma in the mammary gland of a dog

doi: 10.17221/41/2024-VETMED

Figure Lengend Snippet: (A) CK7; (B) VIM); (C) NSE; (D) S-100; (E) Ki-67; (F) CD56; A–F 200 ×

Article Snippet: After this, the slices were allowed to cool and then incubated at room temperature with several primary antibodies, including, Monoclonal Mouse Anti-Human CD56 Clone 123C3 (CD56; Agilent, Carpinteria, USA), Monoclonal Mouse Anti-Human Cytokeratin 7 Clone OV-TL 12/30 (CK7; Agilent, Carpinteria, USA), Monoclonal Mouse Anti-Human Cytokeratin 20 Clone K S 20.8 (CK20; Agilent, Carpinteria, USA), Monoclonal Mouse Anti-Human Oestrogen Receptor α Clone 1D5 (ER; Agilent, Carpinteria, USA), Monoclonal Mouse Anti-Human Ki-67 Antigen Clone MIB-1 (Ki-67; Agilent, Carpinteria, USA), Monoclonal Mouse Anti-Human Neuron-Specific Enolase Clone BBS/NC/VI-H14 (NSE; Agilent, Carpinteria, USA), Anti-S100 antibody 4C4.9 (S-100; Abcam, Cambridge, UK) and Monoclonal Mouse Anti-Vimentin Clone V9 (VIM; Agilent, Carpinteria, USA).

Techniques:

Journal: iScience

Article Title: Pembrolizumab followed by irreversible electroporation of a liver metastasis in pancreatic cancer patients

doi: 10.1016/j.isci.2024.111026

Figure Lengend Snippet:

Article Snippet: Mouse monoclonal anti-human CD56, PE-Cy7, mIgG 1 , κ (CMSSB) , Thermo Fisher , RRID: AB_11181516.

Techniques: Software, Expressing, Isolation